Skip to main content

Table 2 Clinical trials of venetoclax/ABT-199 in combination regimens

From: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Clinical trials Regimens Diseases Responses References
Phase Ib V + R R/R CLL ORR—88 % 86, 87
CR/CRi—32 %
PR—56 %
Phase I V + BR R/R NHL ORR—61.5 % 89
Phase Ib V + BR R/R CLL Not reported 90
Untreated CLL
Phase Ib V + O R/R CLL Not reported 91
Untreated CLL
  1. R/R relapsed/refractory, ORR overall response rate, CLL chronic lymphoid leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia. For regimens: V venetoclax, R rituximab, B bendamustine, O obinutuzumab